Opportunity Information: Apply for PA 10 213
Apply for PA 10 213
- The National Institutes of Health in the education food and nutrition health sector is offering a public funding opportunity titled "Development of Assays for High Throughput screening for use in Probe and Pre therapeutic Discovery (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.233 National Center on Sleep Disorders Research 93.242 Mental Health Research Grants 93.279 Drug Abuse and Addiction Research Programs 93.395 Cancer Treatment Research 93.837 Cardiovascular Diseases Research 93.838 Lung Diseases Research 93.839 Blood Diseases and Resources Research 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research 93.856 Microbiology and Infectious Diseases Research 93.859 Biomedical Research and Research Training 93.866 Aging Research.
- This funding opportunity was created on Oct 14, 2010 and posted on Jun 10, 2010.
- Applicants must submit their applications by Sep 7, 2013. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Public housing authorities/Indian housing authorities Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses City or township governments Special district governments Small businesses Public and State controlled institutions of higher education State governments Independent school districts Private institutions of higher education County governments Native American tribal governments (Federally recognized) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) Native American tribal organizations (other than Federally recognized tribal governments).
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
This NIH funding opportunity (PA 10-213) is a Research Project Grant (R01) program focused on building strong, reliable assays that can be used for high throughput screening (HTS). The main goal is to support groups that can design and validate assays suitable for running on automated screening platforms so large libraries of small molecules can be tested efficiently. The expectation is that these screens will help uncover compounds with useful biological activity that can serve as research probes to better understand a target or pathway, help reveal or confirm new druggable targets, or provide early "pre-therapeutic" starting points (leads) for later drug development work. In other words, the emphasis is on creating the assay tools that make large-scale discovery screening possible, rather than funding a full downstream drug development pipeline.
A central motivation for the announcement is to feed high-quality assays into the NIH Molecular Libraries and Imaging initiative, part of the NIH Roadmap for Medical Research. That initiative was created to expand academic access to capabilities that are usually concentrated in industry, including large and diverse compound collections, robotics and automation to run HTS campaigns, and informatics systems that manage, analyze, and interpret screening data. This FOA is essentially trying to ensure there is a steady flow of scientifically compelling and technically robust assays that can be run at those NIH-supported screening centers (and other similar academic HTS facilities). The assays are expected to be well suited to HTS conditions: reproducible, scalable, compatible with automation, and designed with clear readouts and performance characteristics so they can generate interpretable screening results.
The scientific scope is broad but must align with at least one of the participating NIH Institutes and Centers: NIDDK, NCI, NHLBI, NIA, NIAAA, NIAID, NIDR, NIGMS, and NIMH. In practice, that means assay topics can span cancer biology and treatment, cardiovascular and pulmonary biology, aging, mental health, alcohol-related biology, infectious disease and immunology, diabetes/digestive/kidney disorders, general medical sciences and fundamental biology, and oral and craniofacial health, among others. The FOA also explicitly allows assays that target processes indirectly connected to disease, as long as they are likely to yield meaningful insight into disease-relevant biology. It also highlights interest in assays tied to rare and neglected diseases, reflecting a growing NIH emphasis on making discovery tools available for conditions that are often under-resourced.
From a funding and award-structure perspective, this is a discretionary grant program using the standard NIH R01 mechanism. The announcement does not set a fixed budget cap or a guaranteed number of awards; instead, award size and duration are expected to vary depending on what the proposed assay development requires. Total funding and the number of funded projects depend on the number of submissions, their scientific and technical quality, the proposed timelines, and the requested costs. There is no cost sharing or matching requirement.
Eligibility is intentionally expansive. A wide range of organizations can apply, including public and private institutions of higher education, nonprofits (including those with and without 501(c)(3) status), for-profit organizations (including small businesses, though the mechanism is R01 rather than an SBIR/STTR), local and state governments, tribal governments and tribally controlled institutions, U.S. territories and possessions, and foreign (non-U.S.) organizations and regional organizations. The listing also calls out participation by institutions such as HBCUs, Hispanic-serving institutions, Alaska Native and Native Hawaiian-serving institutions, and faith-based or community-based organizations, indicating the program is open to diverse applicants as long as they can carry out the proposed assay development work at a high standard.
Key administrative details in the source record include a posted date of June 10, 2010, with the opportunity closing on September 7, 2013, and an archive date of October 8, 2013. The awarding agency is the National Institutes of Health, and the full announcement was hosted on the NIH grants guide page for PA 10-213. For access or technical linking issues, the contact listed is the NIH Office of Extramural Research (OER) webmaster.
FAQs: NIH PA 10-213 (R01) - Assay Development for High Throughput Screening (HTS)
What is the NIH funding opportunity PA 10-213?
PA 10-213 is an NIH Funding Opportunity Announcement (FOA) for a Research Project Grant (R01) program focused on developing and validating strong, reliable assays designed for high throughput screening (HTS).
What is the main purpose of this FOA?
The main purpose is to support groups that can design and validate assays that work well on automated screening platforms, enabling efficient testing of large libraries of small molecules. The emphasis is on creating assay tools that make large-scale discovery screening possible.
What kinds of projects are NIH trying to fund under this announcement?
Projects that build technically robust, reproducible, scalable assays suitable for automated HTS. These assays should have clear readouts and well-defined performance characteristics so they can generate interpretable screening results.
Is the goal to fund full drug development?
No. The FOA is aimed at assay development and validation for discovery screening, not at funding a full downstream drug development pipeline. The intended outcomes include discovery-enabling tools and early starting points (leads) rather than complete therapeutic development programs.
Why is assay development for HTS being emphasized?
The FOA is motivated by the need to supply high-quality assays to HTS capabilities supported by NIH, particularly those associated with the NIH Molecular Libraries and Imaging initiative. The idea is to ensure a steady flow of scientifically compelling assays that are technically ready for screening at scale.
How does this FOA connect to the NIH Molecular Libraries and Imaging initiative?
This FOA is designed to help feed high-quality assays into the NIH Molecular Libraries and Imaging initiative (part of the NIH Roadmap for Medical Research). That initiative expands academic access to resources often concentrated in industry, including large compound collections, robotics/automation for HTS, and informatics for screening data management and analysis.
What are expected outputs or benefits from the screens enabled by these assays?
HTS campaigns enabled by these assays are expected to uncover compounds with useful biological activity that can serve as research probes, help reveal or confirm new druggable targets, or provide early "pre-therapeutic" leads for later drug development work.
What does NIH mean by assays that are "well suited to HTS conditions"?
Based on the description provided, assays should be reproducible, scalable, compatible with automation, and built around clear readouts and measurable performance characteristics so screening results can be interpreted reliably.
Is the scientific scope narrow or broad?
The scientific scope is broad, as long as it aligns with at least one participating NIH Institute or Center listed in the FOA.
Which NIH Institutes and Centers are participating in this FOA?
The FOA lists the following participating Institutes and Centers: NIDDK, NCI, NHLBI, NIA, NIAAA, NIAID, NIDR, NIGMS, and NIMH.
What research areas could be relevant under this FOA?
Based on the participating Institutes and Centers, relevant assay topics can include cancer biology and treatment, cardiovascular and pulmonary biology, aging, mental health, alcohol-related biology, infectious disease and immunology, diabetes/digestive/kidney disorders, general medical sciences and fundamental biology, and oral and craniofacial health, among others.
Can the assay target something indirectly related to disease?
Yes. The FOA explicitly allows assays that target processes indirectly connected to disease, as long as they are likely to yield meaningful insight into disease-relevant biology.
Does the FOA mention rare or neglected diseases?
Yes. The FOA highlights interest in assays tied to rare and neglected diseases, reflecting an NIH emphasis on making discovery tools available for conditions that are often under-resourced.
What grant mechanism is used for this opportunity?
This opportunity uses the standard NIH Research Project Grant (R01) mechanism.
Is this a discretionary grant program?
Yes. The description states it is a discretionary grant program using the standard R01 mechanism.
Is there a fixed budget cap for applications?
No. The announcement does not set a fixed budget cap. Award size is expected to vary depending on what the proposed assay development requires.
Is there a guaranteed number of awards?
No. The FOA does not guarantee a number of awards. The number of funded projects depends on factors such as the number of submissions, scientific and technical quality, proposed timelines, and requested costs.
What determines the award size and project duration?
Award size and duration are expected to vary depending on the assay development needs described in the application. Total funding outcomes also depend on the number and quality of submissions, timelines, and requested costs.
Is cost sharing or matching required?
No. The FOA states there is no cost sharing or matching requirement.
Who is eligible to apply?
Eligibility is expansive. Applicants can include public and private institutions of higher education, nonprofits (with and without 501(c)(3) status), for-profit organizations (including small businesses), local and state governments, tribal governments and tribally controlled institutions, U.S. territories and possessions, and foreign (non-U.S.) organizations and regional organizations.
Are small businesses allowed to apply?
Yes. For-profit organizations including small businesses are listed as eligible, although the mechanism for this opportunity is an R01 (not an SBIR/STTR mechanism).
Are foreign (non-U.S.) organizations eligible?
Yes. The eligibility list includes foreign (non-U.S.) organizations and regional organizations.
Are tribal governments and tribally controlled institutions eligible?
Yes. The eligibility list explicitly includes tribal governments and tribally controlled institutions.
Does the FOA encourage applications from specific institution types?
The listing calls out participation by organizations such as HBCUs, Hispanic-serving institutions, Alaska Native and Native Hawaiian-serving institutions, and faith-based or community-based organizations, indicating openness to diverse applicants that can carry out the assay development work at a high standard.
What is the posted date for this opportunity?
The posted date listed in the record is June 10, 2010.
When did the opportunity close?
The opportunity closing date listed is September 7, 2013.
When was the opportunity archived?
The archive date listed is October 8, 2013.
Which agency is the awarding agency?
The awarding agency is the National Institutes of Health (NIH).
Where was the full announcement hosted?
The full announcement was hosted on the NIH grants guide page for PA 10-213.
Who is listed as a contact for access or technical linking issues?
The contact listed for access or technical linking issues is the NIH Office of Extramural Research (OER) webmaster.
What is the overall emphasis of this FOA in one sentence?
The FOA emphasizes creating validated, automation-ready assays that can support large-scale HTS discovery efforts (including NIH-supported screening centers), rather than funding downstream drug development.
Browse more opportunities from the same category: Education Food and Nutrition Health
Next opportunity: Ocean Bottom Seismic Intrument Pools (OBSIP) Management Office
Previous opportunity: NAAEE Careers and Young Professionals
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 10 213
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 10 213) also looked into and applied for these:
| Funding Opportunity |
|---|
| Health Promotion Among Racial and Ethnic Minority Males (R01) Apply for PA 10 236 Funding Number: PA 10 236 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: Case Dependent |
| Lab to Marketplace Tools for Brain and Behavioral Research (SBIR R43/R44) Apply for PA 11 134 Funding Number: PA 11 134 Agency: National Institutes of Health Category: Education Food and Nutrition Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 10 213", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.